CAI
Caris Life Sciences, Inc. NASDAQ$18.47
After hrs
$18.69
+0.00%
Mkt Cap $30.9B
52w Low $16.28
8.4% of range
52w High $42.50
50d MA $19.17
200d MA $26.65
P/E (TTM)
-9.7x
EV/EBITDA
3927.4x
P/B
53.5x
Debt/Equity
0.7x
ROE
-11.8%
P/FCF
674.4x
RSI (14)
—
ATR (14)
—
Beta
1.33
50d MA
$19.17
200d MA
$26.65
Avg Volume
2.3M
About
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | -0.02 | 0.28 | +1500.0% | 19.24 | +10.0% | +4.7% | +7.4% | +0.7% | +3.2% | -0.1% | -12.4% | — |
| Nov 5, 2025 | AMC | -0.08 | 0.08 | +200.0% | 29.21 | +2.7% | -15.7% | -12.3% | -15.1% | -13.9% | -15.2% | -1.2% | — |
| Aug 12, 2025 | AMC | -0.21 | -0.54 | -157.1% | 32.46 | +22.6% | +5.6% | +14.0% | +12.4% | +10.8% | +13.8% | +5.4% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $19.29 | $18.97 | -1.7% | -1.5% | -2.8% | +1.1% | -0.5% | -6.4% |
| Mar 13 | Canaccord Genuity | Maintains | Hold → Hold | — | $17.69 | $17.72 | +0.2% | +2.6% | +7.7% | +4.8% | +4.4% | +6.3% |
| Feb 27 | Baird | Maintains | Outperform → Outperform | — | $19.24 | $21.16 | +10.0% | +4.7% | +7.4% | +0.7% | +3.2% | -0.1% |
| Feb 27 | BTIG | Maintains | Buy → Buy | — | $19.24 | $21.16 | +10.0% | +4.7% | +7.4% | +0.7% | +3.2% | -0.1% |
| Feb 27 | Evercore ISI | Maintains | Outperform → Outperform | — | $19.24 | $21.16 | +10.0% | +4.7% | +7.4% | +0.7% | +3.2% | -0.1% |
| Dec 22 | Canaccord Genuity | Maintains | Hold → Hold | — | $27.94 | $28.22 | +1.0% | +1.9% | +0.2% | +1.1% | +1.1% | +0.0% |
| Aug 13 | Citigroup | Maintains | Buy → Buy | — | $32.46 | $39.80 | +22.6% | +5.6% | +14.0% | +12.4% | +10.8% | +13.8% |
| Aug 13 | Evercore ISI | Maintains | Outperform → Outperform | — | $32.46 | $39.80 | +22.6% | +5.6% | +14.0% | +12.4% | +10.8% | +13.8% |
| Aug 13 | Guggenheim | Maintains | Buy → Buy | — | $32.46 | $39.80 | +22.6% | +5.6% | +14.0% | +12.4% | +10.8% | +13.8% |
Recent Filings
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
I need more specific information about the material agreement to provide meaningful analysis. Could you share the actual details of what the material agreement entails (e.g., partnership, acquisition, financing, termination)?
Apr 2
8-K · 7.01
! Medium
Caris Life Sciences, Inc. -- 8-K 7.01: Regulation FD Disclosure
Caris Life Sciences completed an interim readout of its Achieve 1 study supporting Caris Detect, a multi-cancer early detection test slated for near-term launch, signaling progress toward commercialization of its MCED offering.
Feb 26
Data updated apr 24, 2026 11:41pm
· Source: massive.com